Channel Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
1.350
+0.059 (4.57%)
Jun 11, 2025, 4:00 PM - Market closed
Channel Therapeutics Employees
As of December 31, 2024, Channel Therapeutics had 11 total employees, including 4 full-time and 7 part-time employees. The number of employees increased by 3 or 37.50% compared to the previous year.
Employees
11
Change (1Y)
3
Growth (1Y)
37.50%
Revenue / Employee
n/a
Profits / Employee
-$669,147
Market Cap
8.90M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11 | 3 | 37.50% |
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CHRO News
- 5 weeks ago - Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules - GlobeNewsWire
- 6 months ago - Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine - GlobeNewsWire
- 6 months ago - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model - GlobeNewsWire
- 7 months ago - Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - GlobeNewsWire
- 8 months ago - Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain - GlobeNewsWire
- 8 months ago - Chromocell Announces Amendment to Stock Repurchase Plan - GlobeNewsWire
- 9 months ago - Chromocell to Participate in Life Sciences Investor Forum September 19th - GlobeNewsWire
- 11 months ago - Chromocell Announces Stock Repurchase Plan - GlobeNewsWire